Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Modality
Other
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07657273CT.gov Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07391839CT.gov MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. | — | Recruiting | — | — | — |
NCT06900543CT.gov Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | — | Active Not Recruiting | — | — | — |
NCT06867432CT.gov Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06725121CT.gov Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant | — | Recruiting | — | — | — |
NCT06310590CT.gov Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT05957640CT.gov Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05620771CT.gov Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | — | Recruiting | — | — | — |
NCT05377034CT.gov Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients | — | Recruiting | — | — | — |
NCT07610551CT.gov Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
Show 5 more trialsShow fewer
NCT05016245CT.gov MANDARIN (S6371) | — | Active Not Recruiting | — | — | — |
NCT03300401CT.gov Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization | — | Withdrawn | — | — | — |
NCT02288507CT.gov Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | — | Withdrawn | — | — | — |
NCT01381211CT.gov Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00846131CT.gov Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Yttrium (90 Y) (this asset) | Second Affiliated Hospital of Guangzhou Medical University | P3 | B · 58 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Yttrium (90 Y)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Disease Related To Solid Organ Transplantation | — | P1/2 | CCC · 48 |
| Metastatic Neoplasm | — | P1 | CC · 43 |
| Liver Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Yttrium (90 Y) in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/yttrium-90-y-hepatocellular-carcinoma-104364
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →